Real-world outcomes of newly diagnosed AML treated with venetoclax and azacitidine or low-dose cytarabine in the UK NHSJad Othman, Richard Dillon, Priyanka Mehta et al.|Blood Neoplasia|2024Cited by 36
A Consensus Statement on the Administration of Systemic Bevacizumab in Patients with Recurrent Respiratory PapillomatosisSimon R. Best, Karen B. Zur, Jonathan M. Bock et al.|The Laryngoscope|2024Cited by 14
Outcomes with single-agent gilteritinib for relapsed or refractory <i>FLT3</i>-mutant AML after contemporary induction therapyJad Othman, Richard Dillon, Angela Hwang et al.|Blood Advances|2024Cited by 10